Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07105228 · ClinicalTrials.gov registry record
Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study
A clinical trial, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- 290,000
- Enrollment target
NCT07105228 is a clinical trial that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 290,000 participants.
The verdict
NCT07105228 has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- 290,000 participants
- Enrollment target
Study Summary
This study will describe and estimate the incidence of Retinal Vasculitis (RV) events among patients and patient eyes receiving aflibercept intravitreal (IVT) (Eylea®, aflibercept 2mg) therapy in US clinical practice. The main objective is to describe demographic and clinical characteristics of patients receiving aflibercept 2mg injections, to estimate the incidence of RV and RV plus Intraocular Inflammation (IOI) following aflibercept 2mg injections and to describe characteristics of RV cases.
Interventions
- DRUG aflibercept 2mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290,000 participants |
| Start Date | 2025-07-15 |
| Est. Completion | 2025-09-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07105228
The ClinicalTrials.gov registry entry for NCT07105228 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 290,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which aflibercept 2mg is the first listed.
NCT07105228 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07105228 about?
NCT07105228 is a clinical study titled "Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study". This study will describe and estimate the incidence of Retinal Vasculitis (RV) events among patients and patient eyes receiving aflibercept intravitreal (IVT) (Eylea®, aflibercept 2mg) therapy in US clinical practice. The main objective is to describe demographic and clinical characteristics of pat...
What is the current status of trial NCT07105228?
This trial is currently completed. The enrollment target is 290,000 participants. The study started on 2025-07-15. Estimated completion is 2025-09-15.
What interventions are being tested in trial NCT07105228?
The interventions under investigation include: aflibercept 2mg (DRUG).
Who is sponsoring clinical trial NCT07105228?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.